FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending December 2009
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

Financial Services Authority

 

GlaxoSmithKline plc received on 4 December 2009 from BlackRock, Inc a notification of interests in GlaxoSmithKline plc Ordinary shares of 25 pence each, dated on 1 December 2009. This notice is given in accordance with DTR 5.8.12.

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

   

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
 ii

GLAXOSMITHKLINE PLC 

2 Reason for the notification  (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares

already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

   

3. Full name of person(s) subject to the
notification obligation:
 iii

BlackRock, Inc

4. Full name of shareholder(s) 
 (if different from 3.):iv

 

5. Date of the transaction and date on
which the threshold is crossed or
reached:
 v

1st December 2009

6. Date on which issuer notified:

3rd December 2009

7. Threshold(s) that is/are crossed or
reached: 
vi, vii

Holding has gone above 5%



8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights x

     

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0009252882

N/A

N/A

N/A

N/A

329,124,508

N/A

6.34%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date 
xiii

Exercise/ 
Conversion Period 
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

         
 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments  xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period 
xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

CFD

N/A

N/A

N/A

3,113,781

Nominal

Delta

   

0.06%

 
 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

332,238,289   

6.40%



9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: 
xxi

On 1 December 2009, the Barclays Global Investors (BGI) business was acquired by BlackRock, Inc. The combined holdings of BlackRock, Inc. following this acquisition triggered this disclosure requirement
 

BlackRock Investment Management (UK ) Limited - 332,238,289 (6.40%)

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease
to hold:

N/A

12. Date on which proxy holder will cease to hold
voting rights:

N/A

 

13. Additional information:

BlackRock Compliance Disclosures Team

14. Contact name:

Stuart Watchorn

15. Contact telephone number:

020 7743 5741; stuart.watchorn@blackrock.com

   


 

 

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: December 04 2009

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc